Seguin, Texas — According to state and local economic development sources Fujirebio Diagnostics plans to invest $1,200,000.00 to build out 11,478 square feet of new space in Seguin. The company plans to occupy the new space at 940 Crossroads Blvd in Seguin, on or about October 1, 2022. According to the company website Since our foundation in 1950 in Japan we have acquired a number of best-in-class IVD companies (e.g. Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010), bolstering our capacity to conceive, develop, produce and deliver products of the highest quality across the world. Today, we are part of H.U. Group (previously Miraca Group), a global Japanese healthcare player that favors cross-group R&D synergies and expertise in clinical laboratory testing (SRL), IVD testing solutions (Fujirebio) and other specialized healthcare related activities. As part of H.U. Group we therefore have the capacity to truly understand patient needs and we collaborate closely with clinicians and laboratorians worldwide to develop innovative IVD testing solutions for today and tomorrow.

To learn more about Fujirebio Diagnostics, visit http://www.fujirebio.com/

Company Contact:
Jenny Graham, Chief Financial Officer
https://www.linkedin.com/in/jenny-graham-70423357/
844-544-3787

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved